Edwards Lifesciences' revenue for the fourth quarter fell slightly below expectations as the company sold fewer transcatheter aortic valve replacement (TAVR) devices than expected. Its stock was trading down 4% on Thursday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,